Home › Funds › Artia Global Partners LP › KNSA
Artia Global Partners LP position in KNSA
KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A · Health Care
Artia Global Partners LP reported holding 29,200 shares of KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A) in its Q2 2026 13F filing — a position valued at US$1.9M, representing 0.34% of its reported portfolio and ranking #41 among its reported holdings. Artia Global Partners LP has disclosed KNSA holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Artia Global Partners LP's KNSA position evolved
Artia Global Partners LP first disclosed a stake in KNSA in Q2 2025 at 29,200 shares (US$808K). The position peaked in Q2 2026 at 29,200 shares, worth US$1.9M. Across 5 filings, Artia Global Partners LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 29,200 shares valued at US$1.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 29.20K | $807.96K | New |
| Q3 2025 | 29.20K | $1.13M | Hold |
| Q4 2025 | 29.20K | $1.20M | Hold |
| Q1 2026 | 29.20K | $1.41M | Hold |
| Q2 2026 | 29.20K | $1.87M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A) is a Health Care company. 49 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- Rubric Capital Management LP 4.00M sh · $255.79M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $181.28M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $144.52M · Q2 2026
- Spruce Street Capital LP 918.07K sh · $58.71M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 624.93K sh · $39.96M · Q2 2026
- ORBIMED ADVISORS LLC 420.60K sh · $26.90M · Q2 2026
- Penn Capital Management Company, LLC 368.11K sh · $23.57M · Q2 2026
- Soleus Capital Management, L.P. 246.35K sh · $15.75M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
- ArrowMark Colorado Holdings LLC 215.55K sh · $13.78M · Q2 2026
- STEMPOINT CAPITAL LP 209.23K sh · $13.38M · Q2 2026
More on Artia Global Partners LP
FAQ
How long has Artia Global Partners LP held KNSA?
Artia Global Partners LP has disclosed KNSA holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is Artia Global Partners LP's current position in KNSA?
As of Q2 2026, Artia Global Partners LP holds 29.20K shares of KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A), valued at $1.87M, representing 0.34% of its reported portfolio and ranking #41.
Has Artia Global Partners LP been buying or selling KNSA?
In the latest 13F filing (Q2 2026), Artia Global Partners LP held unchanged its position in KNSA. The position peaked in Q2 2026 at 29.20K shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.